With SensAIR, Gerresheimer presents an innovative platform for on-body drug delivery which can deliver drugs of higher viscosity, such as monoclonal antibodies (mAb). The aim is to provide patients with the best possible support in the subcutaneous delivery of large-volume biologics. The easy-to-use SensAIR On-Body Drug Delivery Device enables patients to start medication in a self-determined manner in familiar surroundings, for example at home. The SensAIR On-Body Drug Delivery Device can be adapted to medications of different viscosities and with different requirements. This applies to the size of the medical device as well as to the needle used, variable cartridge sizes and possible connectivity, for example to the patient’s smartphone. Together with Gerresheimer’s One-Stop-Shop quality promise, which includes a solution from the cartridge to the drug delivery device from a single source, SensAIR enables optimized delivery of biologics. Gerresheimer company will present SensAIR at Pharmapack in Paris October and at CphI Worldwide in Milan in November.

"Everyone benefits from SensAIR: patients, their relatives and doctors. This device is an innovative medical device which, when worn on the body, delivers up to 20 ml of biologics subcutaneously to the patient," says Oliver Haferbeck, Head of the Advanced Technology & Innovation Unit at Gerresheimer and CEO of Sensile-Medical AG. He explains that patients gain significantly in quality of life because they can administer their medication themselves at home. The easy-to-use concept ensures that the patient does not have to carry out any lengthy and complicated preparation steps but can operate the device easily.

More quality of life for the patient
To date, many patients with a wide variety of indications must endure long and stressful infusions in a hospital setting to treat their condition. How much easier would it be if patients could carry out the treatment at home? SensAIR makes life easier for these patients, as they can care for themselves over a longer period and – depending on the indication – only need to visit the doctor or hospital for check-ups.

A simple concept
The SensAIR drug delivery device is characterized by a simple concept which can be costeffectively adapted to different needs, especially patient needs. Gerresheimer thus offers a platform solution which provides a wide range of options regarding the biologic to be applied, starting with the drug flow rate (0.15-1.00 ml/min), through type (for example glass cartridge) and volume (up to 20ml) of the primary packaging, to connectivity. The electronic module can easily be removed from the device after use. This is an important contribution to sustainability.

With this focus, SensAIR is attractive to the market even with varying quantities of devices per year, as existing developments and processes can be adapted in the shortest possible time. The existing technologies and know-how, which have already proven themselves in the market, are consistently pursued in SensAIR. This is a significant advantage in terms of time-to-market, among other things by quickly enabling clinical trials. Gerresheimer is therefore both a partner for the SensAIR device and a supplier and manufacturer of the primary packaging, i.e. the cartridge containing the active ingredient. This represents significant added value as a long-term partner and system supplier.

More about SenAIR
On-Body Devices (gerresheimer.com)

Gerresheimer presents its sustainable innovations and solutions at Pharmapack on October 13 and 14, 2021 in Paris, Paris Expo Porte de Versailles in Hall 7.2 at Booth B60/B64 and from November 09 to 11 at CPhI Worldwide in Milano, Fiera Milano, Hall 6 at Booth 6J10.